Takuya Saito1, Hayao Nakanishi2, Yoshinari Mochizuki3, Seiji Ito4, Yuichi Ito4, Kazunari Misawa4, Yasushi Yatabe5, Keigo Yamamichi6, Eisaku Kondo1,7. 1. Program in Health and Community Medicine, Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan. 2. Division of Oncological Pathology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan. hnakanis@aichi-cc.jp. 3. Department of Surgery, Komaki Municipal Hospital, Komaki, Japan. 4. Department of Gastroenterological Surgery, Aichi Cancer Center Central Hospital, Nagoya, Japan. 5. Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Central Hospital, Nagoya, Japan. 6. Department of Surgery, Osaka Saiseikai Izuo Hospital, Osaka, Japan. 7. Division of Oncological Pathology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan.
Abstract
BACKGROUND: Despite recent clinical trials, the sensitivity and resistance of metastatic gastric cancer to anti-HER2 and anti-EGFR therapy are still unclear. MATERIALS AND METHODS: To clarify the HER2 and EGFR expression status in the metastatic sites, we immunohistochemically compared HER2 and EGFR expression between primary and metastatic tumors from 52 gastric cancer patients with liver metastases and 85 patients with peritoneal metastases. RESULTS: The HER2 positivity rate of primary and metastatic tumors in patients with liver metastases, especially with intestinal-type histology (70.6 and 80.0 %, respectively), was significantly higher than in primary and metastatic tumors (22.4 and 16.4 %, respectively) in patients with peritoneal metastases. HER2 positivity of the primary tumor and liver metastases showed good concordance (87.5 %) in patients with liver metastases. In contrast, the EGFR positivity rate of metastatic tumors (70.1 %) in patients with peritoneal metastases was significantly higher than that of metastatic tumors (37.5 %) in patients with liver metastases. HER2 and EGFR expression tended to be mutually exclusive, and HER2/EGFR double-positive cases were rare in patients with liver or peritoneal metastases. In four such patients with HER2/EGFR double-positive primary tumors, the HER2- and EGFR-positive areas were separate, and corresponding liver metastasis was only positive for HER2 and peritoneal metastasis only positive for EGFR. CONCLUSION: These results indicate that HER2 and EGFR are preferentially expressed in the liver and peritoneal metastases, respectively, which would be potential targets for anti-HER2 and anti-EGFR molecular therapy in metastatic gastric cancer patients.
BACKGROUND: Despite recent clinical trials, the sensitivity and resistance of metastatic gastric cancer to anti-HER2 and anti-EGFR therapy are still unclear. MATERIALS AND METHODS: To clarify the HER2 and EGFR expression status in the metastatic sites, we immunohistochemically compared HER2 and EGFR expression between primary and metastatic tumors from 52 gastric cancerpatients with liver metastases and 85 patients with peritoneal metastases. RESULTS: The HER2 positivity rate of primary and metastatic tumors in patients with liver metastases, especially with intestinal-type histology (70.6 and 80.0 %, respectively), was significantly higher than in primary and metastatic tumors (22.4 and 16.4 %, respectively) in patients with peritoneal metastases. HER2 positivity of the primary tumor and liver metastases showed good concordance (87.5 %) in patients with liver metastases. In contrast, the EGFR positivity rate of metastatic tumors (70.1 %) in patients with peritoneal metastases was significantly higher than that of metastatic tumors (37.5 %) in patients with liver metastases. HER2 and EGFR expression tended to be mutually exclusive, and HER2/EGFR double-positive cases were rare in patients with liver or peritoneal metastases. In four such patients with HER2/EGFR double-positive primary tumors, the HER2- and EGFR-positive areas were separate, and corresponding liver metastasis was only positive for HER2 and peritoneal metastasis only positive for EGFR. CONCLUSION: These results indicate that HER2 and EGFR are preferentially expressed in the liver and peritoneal metastases, respectively, which would be potential targets for anti-HER2 and anti-EGFR molecular therapy in metastatic gastric cancerpatients.
Authors: Ian Smith; Marion Procter; Richard D Gelber; Sébastien Guillaume; Andrea Feyereislova; Mitch Dowsett; Aron Goldhirsch; Michael Untch; Gabriella Mariani; Jose Baselga; Manfred Kaufmann; David Cameron; Richard Bell; Jonas Bergh; Robert Coleman; Andrew Wardley; Nadia Harbeck; Roberto I Lopez; Peter Mallmann; Karen Gelmon; Nicholas Wilcken; Erik Wist; Pedro Sánchez Rovira; Martine J Piccart-Gebhart Journal: Lancet Date: 2007-01-06 Impact factor: 79.321
Authors: Kab Choong Kim; Young Wha Koh; Heung-Moon Chang; Tae Hwan Kim; Jeong Hwan Yook; Byung Sik Kim; Se Jin Jang; Young Soo Park Journal: Ann Surg Oncol Date: 2011-04-06 Impact factor: 5.344
Authors: Amir Onn; Arlene M Correa; Michael Gilcrease; Takeshi Isobe; Erminia Massarelli; Corazon D Bucana; Michael S O'Reilly; Waun K Hong; Isaiah J Fidler; Joe B Putnam; Roy S Herbst Journal: Clin Cancer Res Date: 2004-01-01 Impact factor: 12.531
Authors: Angela N Bartley; Mary Kay Washington; Christina B Ventura; Nofisat Ismaila; Carol Colasacco; Al B Benson; Alfredo Carrato; Margaret L Gulley; Dhanpat Jain; Sanjay Kakar; Helen J Mackay; Catherine Streutker; Laura Tang; Megan Troxell; Jaffer A Ajani Journal: Am J Clin Pathol Date: 2016-11-14 Impact factor: 2.493
Authors: Q Li; H Li; H Jiang; Y Feng; Y Cui; Y Wang; Y Ji; Y Yu; W Li; C Xu; S Yu; R Zhuang; T Liu Journal: Clin Transl Oncol Date: 2017-11-22 Impact factor: 3.405
Authors: Eirini Pectasides; Matthew D Stachler; Sarah Derks; Yang Liu; Steven Maron; Adam J Bass; Daniel V Catenacci; Mirazul Islam; Lindsay Alpert; Heewon Kwak; Hedy Kindler; Blase Polite; Manish R Sharma; Kenisha Allen; Emily O'Day; Samantha Lomnicki; Melissa Maranto; Rajani Kanteti; Carrie Fitzpatrick; Christopher Weber; Namrata Setia; Shu-Yuan Xiao; John Hart; Rebecca J Nagy; Kyoung-Mee Kim; Min-Gew Choi; Byung-Hoon Min; Katie S Nason; Lea O'Keefe; Masayuki Watanabe; Hideo Baba; Rick Lanman; Agoston T Agoston; David J Oh; Andrew Dunford; Aaron R Thorner; Matthew D Ducar; Bruce M Wollison; Haley A Coleman; Yuan Ji; Mitchell C Posner; Kevin Roggin; Kiran Turaga; Paul Chang; Kyle Hogarth; Uzma Siddiqui; Andres Gelrud; Gavin Ha; Samuel S Freeman; Justin Rhoades; Sarah Reed; Greg Gydush; Denisse Rotem; Jon Davison; Yu Imamura; Viktor Adalsteinsson; Jeeyun Lee Journal: Cancer Discov Date: 2017-10-04 Impact factor: 39.397
Authors: Roberto de Moraes Cordts Filho; Paulo Kassab; Laura Carolina Lopez Claro; Mabel Tatty de Medeiros Fracassi; Patrícia Colombo-Souza; Daniel Kenji Fukuhara; Fábio Rodrigues Thuler; Wilson Rodrigues de Freitas Junior; Elias Jirjoss Ilias; Carlos Alberto Malheiros Journal: ScientificWorldJournal Date: 2016-12-25
Authors: A Creemers; E Ter Veer; L de Waal; P Lodder; G K J Hooijer; N C T van Grieken; M F Bijlsma; S L Meijer; M G H van Oijen; H W M van Laarhoven Journal: Sci Rep Date: 2017-06-09 Impact factor: 4.379
Authors: Aafke Creemers; Eva A Ebbing; Gerrit K J Hooijer; Lisanne Stap; Rajni A Jibodh-Mulder; Susanne S Gisbertz; Mark I van Berge Henegouwen; Maurits L van Montfoort; Maarten C C M Hulshof; Kausilia K Krishnadath; Martijn G H van Oijen; Maarten F Bijlsma; Sybren L Meijer; Hanneke W M van Laarhoven Journal: Oncotarget Date: 2018-06-01